This study assessed the capacity of a 60-minute nap to reverse the sedating and performance-disruptive effects of et hanol, triazolam, and Diphenhydramine. Twelve healthy, young men received (at 0800 to 0830) .6 glkg et hanol and a placebo pill, .25 mg triazolam and ethanol placebo, 50 mg Diphenhydramine and ethanol placebo, and a placebo pill and ethanol placebo on each of 2 days in a Latin Square design. On one treatment day (at 0900 hour) subjects were allowed a 60-minute nap and on the other a sleep latency test (no nap 
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This study assessed the capacity of a 60-minute nap to reverse the sedating and performance-disruptive effects of et hanol, triazolam, and Diphenhydramine. Twelve healthy, young men received (at 0800 to 0830) .6 glkg et hanol and a placebo pill, .25 mg triazolam and ethanol placebo, 50 mg Diphenhydramine and ethanol placebo, and a placebo pill and ethanol placebo on each of 2 days in a Latin Square design. On one treatment day (at 0900 hour) subjects were allowed a 60-minute nap and on the other a sleep latency test (no nap Roehrs et al. 1984) . Ben zodiazepines also hasten sleep onset after daytime ad ministration, again in a dose-related manner (Roehrs et aI. 1988) . Finally, ethanol also has a dose-related effect on sleep latency as measured by the MSLT (Zwyghui zen- . All these drugs also disrupt 1100, 1300, 1500, and 1700) and divided attention performance assessed (at 1130). The nap reversed the sedative effects of ethanol and Diphenhydramine and reduced those of triazolam (on MSLT). The nap reduced the performance-disruptive effects of ethanol and Diphenhydramine but not those of triazolam. Given the differing neurobiological mechanisms of these drugs, the data suggest that some of their effects are nonspecific and result from activation of sleep mechanisms that a nap can reverse. [Neuropsychopharmacology 9:239-245, 1993J performance on various psychomotor, cognitive, and memory tasks, and the disruptive effects associated with some have been found to relate to the hypnotic potency of the specifIc drug and dose (Roehrs et al. 1993 ; Merlotti et aI. 1992 ).
Although they share sedative and performance disruptive effects, these drugs are thought to produce their effects through quite different neurobiologic mech anisms. The benzodiazepines are known to facilitate chloride conductance at the GABA receptor complex (Mendelson et al. 1984) . Ethanol also alters chloride con ductance, but its sedating effects appear to be due to enhancement of calcium uptake (Mendelson 1989) . Fi nally, the antihistamines act at central histamine recep tors, blocking the action of histamine, now considered a waking amine (Schwartz et al. 1982) .
The common sedative and performance-disruptive effects of these drugs, given their differing neurobio logic mechanisms, suggest that these effects are non specifIc and may result from activation of sleep mecha nisms. If the sedation is due to activation of a sleep drive, then sleep per se should reverse these effects.
One previous study of the effects of a 60-minute nap following drug administration showed that the nap re-0893-133X/93/$6.00 duced the sedative and performance-disruptive effects of a moderate ethanol dose (Roehrs et al. 1990 ). The question arises as to whether a nap will similarly re verse or reduce the sedative effects associated with a benzodiazepine and a HI antihistamine.
METHODS

Subjects
The subjects were 12 healthy young men, aged 21 to 35 years (mean 24.3 ± 2.4 years). The subjects did not smoke, currently use licit or illicit drugs (confIrmed by a urine drug screen), and reported drinking an aver age of 1 to 14 alcoholic drinks per week. They were in good physical and mental health based on their medi cal and drug-use histories, a physical examination, and laboratory analysis of blood and urine samples. They reported normal sleep habits with nocturnal sleep laten cies of 30 minutes or less, no sleep-maintenance prob lems, no habitual daytime napping, a regular sleep schedule with bedtime and time of arising not varying by more than 2 hours, and no clinical evidence of sleep disorders. Each signed an informed consent (approved by the Institutional Review Board) and was paid for par ticipation.
Procedure
The subjects qualifying on the initial screening were asked to come to the sleep laboratory for a one-night screening and laboratory adaptation. Each reported 1 hour prior to their usual bedtime, and electrodes were attached at standard Rechtschaffen and Kales (1968) placements to record electroencephalograms (EEGs, central and occipital), electrooculograms (EOGs, left and right outer canthi), and an electromyogram (EMG, submental) with the addition of a tibialis EMG to de tect leg movements and a nasal/oral thermistor to de tect respiratory disturbance. They went to bed for 8 hours while their sleep was monitored. Those with a sleep efficiency (sleep time per time in bed) of 85% or less and any evidence of leg movements or respiratory disturbance were excluded.
The following day the MSLT was administered at 1000, 1200, 1400, and 1600 according to standard proce dures (Carskadon et al. 1986 ). For each latency test sub jects went to bed in a dark, quiet room and were in structed to try to fall asleep while EEGs (always including the occipital), EOGs, and the EMG (submen tal) were monitored. Subjects were awakened after 1 minute of unambiguous stage 1 sleep, the fIrst signs of stage 2 or rapid-eye movement (REM) sleep, or 20 minutes of continuous wake according to the standards NEURO PSYCHOPHARMACOLOGY I993-VOL. 9, NO.3 of Rechtschaffen and Kales (1968) . Subjects with a mean daily sleep latency (minutes to fIrst epoch of sleep) of 10 minutes or more were included.
QualifIed subjects underwent each of four drug ethanol treatment conditions lasting 2 days (a total of 8 days), with conditions presented in a repeated mea sures Latin Square design. The treatment condition s were .6 g/kg ethanol and a placebo pill, 50 mg Diphen hydramine and ethanol placebo, .25 mg triazolam and ethanol placebo, and a placebo pill and ethanol placebo. The ethanol was prepared in a 1:4 ratio with 80 proof vodka added to tonic water, and the ethanol placebo consisted of the tonic water with three drops of vod ka floated on the surface for gustatory and olfactory cues. The drugs and placebos were presented in similar look ing opaque capsules. Each condition included a nap an d a no-nap day (the 2 days of each condition) that were counterbalanced within each condition. The conditions were presented once a week on the same 2 weekdays.
Prior to each experimental day subjects spent 8 hours in bed (2300-0700), while sleep was monitored with an actigraph (Levine et al. 1986) . Subjects arose at 0700, used the toilet, and ate a small breakfast con sisting of a noncaffeinated beverage and a roll. They then received the pill at 0800 and consumed the etha nol or placebo drink between 0800 and 0830, pacing their drinking over the 30 minutes. At 0900 subjects went to bed for a 60-minute nap (nap condition) or had a sleep latency test (no-nap condition). In all conditions latency tests were then conducted at 1100,1300,1500, and 1700 as described in the screening. Subjects were allowed to leave the laboratory after the last latency test and were required to return to the laboratory 1 hour before bed time on the next study day.
The pharmacokinetics of the drugs used in this study are known to differ. Blood samples were not drawn in this study to characterize plasma concentra tion curves. Plasma concentration curves following a drug administration at 0900 (at 0800 drug administra tion was used in this experiment to provide for the 60-minute nap) for the doses of ethanol, triazolam, and Diphenhydramine used in this experiment can be found in a previous paper (Roehrs et al. 1993) . Because some studies have found differences in breath-ethanol co n centration (BEC) as a function of sleep versus wake, BEC was measured at approximately 0900, 1100, 1300, 1500 , and 1700 just prior to each of the latency tests (or the 60-minute nap). The BEC measurement was conducted every day, regardless of whether ethanol or eth anol placebo had been administered. It was measured using an Alcotest 7010 National Draeger Breathalyzer.
At 1130 a IS-minute divided attention performance test was administered. Each subject was trained on the divided attention test during the screening day. The test was presented on a video screen controlled by an NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO .3
Apple IIc computer. During the test, subjects were seated in front of the video screen with the task of track ing a moving target using a joystick that was maneu vered with the preferred hand. At the same time, sub jects responded to the appearance of a target stimulus (a white circle) in the center or in the periphery of the screen by pressing a button located adjacent to the joystick. Reaction times (RT) to the central stimulus, the peripheral stimulus, and the tracking deviations were recorded.
During each day, subjects were instructed to refrain from any napping and caffeine use and were continu ously monitored throughout the day to ensure compli ance. Alcohol and drug use other than that required in the study was also prohibited. Subjects were told that urine samples would be collected during the study and tested for the presence of unauthorized use of drugs.
The MSLT was scored for sleep latency according to the standards of Rechtschaffen and Kales (1968) 
Breath-Ethanol Concentration
The BEC did not differ significantly on the nap and no nap days, and the data are combined. Average BEC over both days at 30 minutes after consumption (0900) was .044% ± .014%. At 1100 the BEC was .037% ± .013%, it declined to .014% ± .013% at 1300, and reached zero at 1500. There was a signifIcant time of test effect (F = 67.76, p< .001), with the BEC at 0900 differing from that at 1300, 1500, and 1700 and the BEC at 1100 similarly differing from that of the last three tests. Finally, the BEC at 1300 diff ered from those at 1500 and 1700.
Nap Effects on Mean Sleep Latency (MSLT)
The mean daily sleep latency with and without a nap after ethanol consumption is compared to the placebo conditions in Figure 1 . In the analysis comparing the four drug and nap combinations there was an overall condition effect (F = 11.21, P < .001). 
Time Effects on Sleep Latency (MSLT)
Sleep latency On each test (0900, 1100, 1300, 1500, and 1700) is presented in Table 2 . On the table the nap versus no-nap conditions are combined, as there were no signifIcant triple interactions (i.e., nap by time by drug).
In the analysis of ethanol effects a signifIcant time (F = 5.00, P < .006) and time by ethanol interaction (F = 3.27, P < .03) were found. Ethanol differed from placebo On the fITst two tests only (p < .05). In the analysis of Diphenhydramine effects a signifIcant time (F = 8.94, P < .001) and time by Diphenhydramine interaction (F = 4.74, P < .01) were found. Drug effects were found on the fITst three tests (p < .05). Finally, for triazolam a signifIcant time (F = 16.22, P < .0001) and time by tria zolam interaction (F = 13.91, P < .0001) were found.
Drug effects after triazolam appeared On the fITst three tests (p < .05).
Nap Effects on Psychomotor Performance (Divided Attention)
The divided attention measures for each drug condi tion with and without a nap are presented in Table 3 . As with tracking, main effects of condition in the ethanol analysis were found on peripheral reaction time (F = 4.09, p< .03) and central reaction time (F = 3.19, p< .04). Disruptive effects were seen in that the etha nol-no-nap condition diff ered from the placebo-no-nap condition for each measure (p < .005 and p < .01, respec tively). The nap reduced this effect on central reaction time (ethanol-nap condition was intermediate between the placebo-no-nap and ethanol-no-nap conditions) but had no effect on the peripheral reaction time (ethanol-nap condition diff ered from placebo-no-nap condition, p < .03, did not diff er from the ethanol-no nap condition).
On the Diphenhydramine analysis of nap effects, main effects of condition were found for tracking (F = 5.04, P < .005), peripheral reaction time (F = 4.35, P < .03), and central reaction time (F = 3.23, P < .04). Diphenhydramine was associated with a disruption of each parameter (Diphenhydramine-no-nap condition diff ered from placebo-no-nap condition, p < .008, p < .01, P < .04, respectively). The nap reduced this effect on central reaction time (Diphenhydramine-nap con di tion did not differ from placebo-no-nap condition) but had no effect on tracking or peripheral reaction time.
Finally, in the triazolam analysis of nap effects con dition main effects were found for tracking (F = 5.82, P < .003), peripheral reaction time (F = 7.91, P < .001), and central reaction time (F = 7.90, P < .001). Triazo lam was associated with a disruption of each parame ter (triazolam-no-nap condition diff ered from pla cebo-no-nap condition, p < .01, p < .009, p < .007, Table 3 . Divided Attention Performance respectively). The nap failed to reverse or reduce the disruptive effects of triazolam (for each measure triazolam-nap condition differed from placebo-no-nap condition, p< .006, p< .001, p< .001, respectively, and did not diff er from the triazolam-no-nap condition).
Drug Effects on Nap Sleep Table 4 presents the sleep stage parameters on the 60-minute nap for each of the four drug conditions. Com paring the drug conditions, a main effect of condition was found for total sleep time (F = 8.38, P < .02) with the triazolam condition diff ering from placebo (p< .05). The combination of percent wake and stage 1 sleep also showed condition effects (F = 3.39, p< .04), again with triazolam differing from placebo (p < .05). Finally, for percentage stage 3/4 sleep there was a condition effect (F = 3.08, P < .05), and on the post hoc testing Diphen hydramine diff ered from placebo.
DISCUSSION
The 6O-minute nap reversed the sedative effects (as mea sured by MSLT) of ethanol (.6 g/kg) and Diphenhydra mine (50 mg) and reduced the effects of triazolam (.25 mg). The 60-minute nap reduced the performance disruptive effects of ethanol and Diphenhydramine but not those of triazolam. In part, the diff erential hypnotic effects of these drugs at the doses studied can explain Data are means ± SD. 89.5 ± 12.4 30.3 ± 22.8 59.6 ± 26.9 0. 0 ± 0.0 2.3 ± 6.0 81.4 ± 64.7 96.3 ± 33.4 0.0 ± 0.0 2.8 ± 5.1 84.9 ± 52.0 6.0 ± 1. 9
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the diff erences in the effectiveness of the nap in revers ing or reducing the drug effect. In Figure 4 the diff er ing hypnotic effects of the drugs are compared to illus trate this point. Triazolam produced the greatest reduction in sleep latency, and the nap was least effec tive in reversing the effects of triazolam. On the other hand, ethanol was associated with the smallest reduc tion in sleep latency, and the nap was most effective in reversing the effects of ethanol. The relative potency of triazolam to the other drugs also is illustrated by the drug effects on nap sleep. Tria zolam among the active drugs increased sleep on the 60-minute nap and also reduced the percentage of light sleep (stage 1). Numerically, the Diphenhydramine values fell between those of triazolam and placebo. Diphenhydramine also increased percentage stage 3/4 sleep, which was not seen with triazolam. But in all night studies the benzodiazepines have been consis tently shown to reduce stage 3/4 sleep. Consequently, with triazolam one would expect to fmd no effect or even a reduction in stage 3/4 on the nap.
An alternative viewpoint regarding the hypothe sis that triazolam effects were not reversed because of the relatively greater hypnotic effects of triazolam can be mentioned. It could be argued that the greater amount of sleep on the 60-minute nap with triazolam should produce improved performance and alertness. But, the difference in sleep time between placebo and triazolam was 12 minutes (41 vs. 53 minutes). In 24-hour-sleep-deprived normals a 15-minute nap failed to improve sleepiness or alertness, but 30-to 120-minute naps did (Lumley et al. 1986 ). The subjects in this study were fully rested, having had 7 to 8 hours of sleep the night before each daytime assessment. It is unlikely that the increased nap sleep in the triazolam condition would result in detectable performance effects. The point must be made that conclusions regard ing the effects of the drugs and the capacity of the 60-minute nap to reverse those effects in this study are limited by the fact that concurrent plasma concentra tions of triazolam and diphenhydramine were not ob tained. In a previous study plasma concentration was measured, and peak concentrations of triazolam and Diphenhydramine at the doses used in this study were seen 3.5 hours after administration at 0900 (Roehrs et al. 1993) . The performance testing in this study began 3.5 hours post drug administration, which was proba bly close to the peaks of triazolam and Diphenhydra mine. The peak ethanol concentration as measured by the BEC occurred much earlier, sometime between 0900 and 1100.
The effectiveness of the nap in reversing the effects of ethanol replicates the nndings of a previous study. In that study .6 g/kg ethanol was administered, and a peak BEC of .04% was achieved. A 60-minute nap com pletely reversed the sedating effects of ethanol as mea sured by the MSLT (Roehrs et al. 1990 ). That study did not include a performance assessment, as did the p res ent study. In this study, with similar peak BECs (.044%), performance effects were reduced but not reversed. The reduction in performance effects, as opposed to a com plete reversal of MSLT effects as found in the previous and present study, may reflect two factors. First, the MSLT may be a more sensitive measure with less vari ability, which is thus capable of more readily detecting the nap effects. Second, there may be components necessary to performing a divided attention task that are affected by ethanol but are not associated with sleep iness and therefore are not improved by the nap .
The modest effect of the nap in reducing the effects of .25 mg triazolam can be compared to the ftndings of another study, in which caffeine was used to coun teract the disruptive effects of triazolam .50 mg on per formance measures . Unfortunately, the triazolam doses diff ered between these two studies. But, in that study both 4 mg/kg and 8 mg/kg caffeine did not reduce the sedative and amnestic effects of tria zolam 2 hours after administration. Even 4.5 hours postadministration 4 mg/kg caffeine was unable to re duce the effects of triazolam, although the 8-mg/kg dose completely reversed the effects. It would be interest ing to compare the potency of caffeine to that of a nap in reversing sedative drug effects.
It is interesting to consider the sedative and per formance-disruptive effects of Diphenhydramine 50 mg relative to those of ethanol and triazolam. Diphenhydra mine in the 50 mg dose appeared to be intermediate to ethanol and triazolam in this study. These results can be discussed in the context of the only previous study to have directly compared the sedative effects of an antihistamine to that of a benzodiazepine (Nichol son and Stone 1986). That study found that triprolidine 2.5 mg produced similar sedative effects to those of Di azepam 5 mg, although there were some differences in the time course of the sedative effects. Triazolam .25 mg would generally be considered more equivalent to 10 mg Diazepam in terms of sedative effects. How the sedative effects of triprolidine might compare to Di phenhydramine is not known.
The mechanism by which the sedative effects of these drugs is reversed is not certain. We have hypothe sized that all these drugs are activating homeostatic sleep mechanisms, that is, a sleep drive. The neurobi ology of the sleep drive is not known. Whatever its neu robiology, it seems clear that the central nervous sys tem (CNS) has the capacity to monitor the state of sleepiness or alertness. The concurrent status of sleep iness or alertness alters the sensitivity of the CNS to sedating drugs. In addition, whether the sleep drive is activated by sleep deprivation or a sedative drug, sleep per se can reduce or reverse the sleepiness. On the other side, the accumulation of sleep (i.e., increased alertness) prior to administration of a sedative drug can blunt the sedative effects of that drug. This has been demonstrated in humans with ethanol (Roehrs et al. 1989) and recently in animals with the benzodiazepine triazolam (Edgar et al. 1991) . In each study, sleep time was increased prior to the administration of the drug, and the sedative effects of the drug seen after normal amounts of sleep were not observed.
